Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Sionna Therapeutics, Inc.NASDAQ: SION
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 2.3% from a year ago
Common stock stood at $45K at the end of Q1 FY2026, up 2.3% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +182.3% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +2.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 45K USD
- Year-over-year change
- +800.0%
- 3-year CAGR
- +182.3%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 45K | +800.0% |
| FY2024 | 2024-12-31 | 5K | +150.0% |
| FY2023 | 2023-12-31 | 2K | +0.0% |
| FY2022 | 2022-12-31 | 2K | — |
Common Stock vs competitors
How SION compares with its peers on the latest reported figures
- SION's Mar 2026 common stock of $45K is the 8th highest of the 11 companies compared; the peer median is $66K.
- Its year-over-year change of +2.3% is the 10th highest of 11, against a peer median of +13.1%.
- Common stock amounts to 0.0% of total assets for SION, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $2.14B | +22.7% | +46.5% | 576.9% | |
| Sep 2026 | $1.15B | +4.2% | +7.1% | 97.5% | |
| Sep 2026 | $996.19M | +25.4% | +3.0% | 66.4% | |
| Sep 2026 | $79K | +19.7% | +12.5% | 0.0% | |
| Jun 2026 | $72K | +12.5% | +36.4% | 0.0% | |
| Mar 2026 | $60K | +1.7% | +12.6% | 0.0% | |
| Mar 2026 | $50K | +13.6% | +32.6% | 0.0% | |
| Mar 2026 | $45K | +2.3% | +182.3% | 0.0% | |
| Mar 2026 | $25K | +4.2% | +6.3% | 0.0% | |
| Mar 2026 | $18K | +12.5% | +6.7% | 0.0% | |
| Sep 2026 | $11K | +22.2% | +122.4% | 0.0% | |
| Peer median (excluding SION) | $66K | +13.1% | +12.6% | 0.0% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.